Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations
- PMID: 24362842
- PMCID: PMC3969764
- DOI: 10.1007/s00520-013-2068-0
Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations
Abstract
Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is increasing with introduction of new and combination cancer pharmacotherapies. This study evaluated associations between clinical and self-report measurements and current perception threshold (CPT), a neuroselective measure of sensory nerve function that may detect asymptomatic CIPN damage.
Methods: Data for this secondary analysis were from a prospective, observational study using CPT to evaluate CIPN. Bivariate mixed models, accounting for the intraclass correlation between repeated patient assessments, were used to assess the relationship between CPT at each frequency (5, 250, and 2,000 Hz) and each subjective measure (Neuropathic Pain Scale, FACT-GOGntx) and objective measurement (quantitative sensory testing, deep tendon reflexes, and grip strength).
Results: A total of 29 chemotherapy-naïve subjects with various cancer types had a mean age of 56.7 (SD 10.4); nine subjects developed CIPN grade >1 using NCI CTC-AE criteria. Cold detection thresholds were inversely associated with CPT 5 [b(95 % CI) = -2.5(-4.5, -0.5)] and CPT 2,000 [-7.5(-11.8, -3.3)] frequencies. FACT GOG-ntx quality of life (QoL) scale and neurotoxicity and function subscales were inversely associated with CPT 2,000 [-1.8 (-3.5, -0.05), -2.2 (-4.2, -0.2), and -5.4 (-9.8, -0.9), respectively], indicating worsening QoL, impairment, and function as hypoesthesia increases.
Conclusions: CPT 2,000 may identify impending worsening of patient-reported outcomes such as QoL.
Similar articles
-
Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity.Neurology. 2021 Aug 17;97(7):e660-e672. doi: 10.1212/WNL.0000000000012300. Epub 2021 Jun 2. Neurology. 2021. PMID: 34078718 Free PMC article.
-
Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.J Natl Compr Canc Netw. 2023 Feb;21(2):125-132.e3. doi: 10.6004/jnccn.2022.7074. J Natl Compr Canc Netw. 2023. PMID: 36791763
-
Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children's Oncology Group AHOD 1331 study.J Patient Rep Outcomes. 2023 Nov 10;7(1):113. doi: 10.1186/s41687-023-00653-0. J Patient Rep Outcomes. 2023. PMID: 37947987 Free PMC article.
-
[Chemotherapy-induced peripheral neuropathy; impact on quality of life].Ned Tijdschr Geneeskd. 2014;158:A7455. Ned Tijdschr Geneeskd. 2014. PMID: 25315326 Review. Dutch.
-
Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings.J Neurol Neurosurg Psychiatry. 2019 Dec;90(12):1361-1369. doi: 10.1136/jnnp-2019-320969. Epub 2019 Jun 29. J Neurol Neurosurg Psychiatry. 2019. PMID: 31256000 Review.
Cited by
-
Spinal cord stimulation prevents paclitaxel-induced mechanical and cold hypersensitivity and modulates spinal gene expression in rats.Pain Rep. 2019 Sep 12;4(5):e785. doi: 10.1097/PR9.0000000000000785. eCollection 2019 Sep-Oct. Pain Rep. 2019. PMID: 31875188 Free PMC article.
-
Chemotherapy-Induced Neuropathy in Cancer Survivors.J Pain Symptom Manage. 2017 Aug;54(2):204-218.e2. doi: 10.1016/j.jpainsymman.2016.12.342. Epub 2017 Jan 4. J Pain Symptom Manage. 2017. PMID: 28063866 Free PMC article.
-
Pain in Platin-Induced Neuropathies: A Systematic Review and Meta-Analysis.Pain Ther. 2018 Jun;7(1):105-119. doi: 10.1007/s40122-017-0092-3. Epub 2017 Dec 1. Pain Ther. 2018. PMID: 29196945 Free PMC article. Review.
-
Framework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN).Support Care Cancer. 2023 Apr 22;31(5):293. doi: 10.1007/s00520-023-07734-2. Support Care Cancer. 2023. PMID: 37086308 Free PMC article. Review.
-
Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind, randomized study.J Gynecol Oncol. 2021 Sep;32(5):e73. doi: 10.3802/jgo.2021.32.e73. Epub 2021 Jun 1. J Gynecol Oncol. 2021. PMID: 34132071 Free PMC article.
References
-
- Edwards BK, et al. Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. Journal of the National Cancer Institute. 2005;97(19):1407–1427. - PubMed
-
- World Health Organization. International Classification of Functioning, Disability, and health (ICF) 2001.
-
- Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006;24(10):1633–42. - PubMed
-
- Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer. 2006;42(1):24–30. - PubMed
-
- Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol. 2000;11(5):509–13. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical